Skip to main content
SpringerLink
Log in

Effects of long-term pravastatin treatment on spermatogenesis and on adrenal and testicular steroidogenesis in male hypercholesterolemic patients

  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

To evaluate the influence of an hydrophilic statin, pravastatin, on adrenal and testicular steroidogenesis and spermatogenesis, eight male hypercholesterolemic patients were studied. All patients observed a hypocholesterolemic diet and received placebo for 4 weeks followed by pravastatin (20 mg/die) for 6 months. Before, during (4th-5th week) and at the end (23th-24th week) of active treatment, CRH (1 µg iv), ACTH (Synacthen 250 µg iv) and human CG (HCG 3000 IU im) tests were performed in addition to semen analysis. Pravastatin significantly reduced total cholesterol (20.3%), calculated LDL-cholesterol (24.6%) and apolipoprotein B (10.5%), increased apolipoprotein A1 (16.1%) and did not influence plasma HDL-cholesterol and triglycerides. Basal plasma cortisol, aldosterone, androstenedione, testosterone and oestradiol did not change under active treatment. Pravastatin administration affected neither adrenal hormone responses to CRH and ACTH or testicular response to HCG nor spermatogenesis in respect of motility, morphology and sperm count. In conclusion, long-term pravastatin treatment, at doses effective in improving lipid profile, did not influence testicular reproductive and endocrine function and did not interfere with basal and stimulated adrenal activity of male hypercholesterolemic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brown M.S., Kovanen P.T., Goldstein J.L. Receptor mediated uptake of lipoprotein cholesterol and its utilization for steroid synthesis in the adrenal cortex. Recent Prog. Horm. Res. 35: 215, 1979.

    PubMed  CAS  Google Scholar 

  2. Gwynne J.T., Strauss J.F. The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic cells. Endocr. Rev. 3: 299, 1982.

    Article  PubMed  CAS  Google Scholar 

  3. Tureck R.W., Strauss III J.F. Progesterone synthesis by luteinized human granulosa cells in culture: the role of de novo sterol synthesis and lipoprotein-carried sterol. J. Clin. Endocrinol. Metab. 54: 367, 1982.

    Article  PubMed  CAS  Google Scholar 

  4. Illingworth D.R., Kenny T.A., Orwoll E.S. Adrenal function in heterozygous and homozygous hypobetalipoproteinemia. J. Clin. Endocrinol. Metab. 54: 27, 1982.

    Article  PubMed  CAS  Google Scholar 

  5. Illingworth D.R., Lees A.M., Lees R.S. Adrenal cortical function in homozygous familial hypercholesterolemia. Metabolism 30: 1045, 1983.

    Article  Google Scholar 

  6. Biemer J.J., McCammon R.E. The genetic relationship of abetalipoproteinemia and hypobetalipoproteinemia: a report of occurrence of both diseases within the same family. J. Lab. Clin. Med. 85: 556, 1975.

    PubMed  CAS  Google Scholar 

  7. Grundy S.M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med. 319: 24, 1988.

    Article  PubMed  CAS  Google Scholar 

  8. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 89: 1329, 1994.

    Google Scholar 

  9. Tobert J.A., Bell G.D., Birtwell J., James I., Kurovetz W.R., Pryor J.S., Buntinx A., Holmes I.B., Chao Y.S., Bolognese J.A. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, in healthy volunteers. J. Clin. Invest. 69: 913, 1982.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  10. Famsworth W.H., Hoeg J.M., Maher M., Brittain E.H., Sherins R.J., Brewer Jr H.B. Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin. J. Clin. Endocrinol. Metab. 65: 546, 1987.

    Article  Google Scholar 

  11. Laue L., Hoeg J.M., Barnes K., Loriaux D.L., Chrousos G.P. The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway. J. Clin. Endocrinol. Metab. 64: 531, 1987.

    Article  PubMed  CAS  Google Scholar 

  12. Jay R.H., Sturley R.H., Stirling C., McGarrigle H.H.G., Kats M., Reckless J.P.D., Betteridge J. Effects of pravastatin and colestiramin on gonadal and adrenal steroid production in familial hypercholesterolemia. Br. J. Clin. Pharmacol. 32: 417, 1991.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  13. Mol M.J.T.M., Stanlenhoef F.H., Stuyt P.M., Hermus A.R.M.M., Demacker P.N.M., Van T Laar A. Effects of inhibition of cholesterol synthesis by simvastatin on the production of adrenocortical steroid hormones and ACTH. Clin. Endocrinol. (Oxf.) 31: 679, 1989.

    Article  CAS  Google Scholar 

  14. Prihoda J.S., Pappu A.S., Smith F.E., Illingworth D.R. The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia. J. Clin. Endocrinol. Metab. 72: 567, 1991.

    Article  PubMed  CAS  Google Scholar 

  15. Azzarito C., Boiardi L., Zini M., Agosti A., Dotti C., Biagi R., Portioli I. Long-term therapy with high-dose simvastatin does not affect adrenocortical and gonadal hormones in hypercholesterolemic patients. Metabolism 41: 148, 1992.

    Article  PubMed  CAS  Google Scholar 

  16. Illingwoth D.R., Corbin D. The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA 82: 6291, 1985.

    Article  Google Scholar 

  17. Yamaguchi K., Nakamura N., Uzawa N. Blocking 3-hydroxy-3-methyl glutaryl coenzyme A reductase with ML-236 B enhances the plasma cortisol response to adrenocorticotropin in patients with hypercholesterolemia. J. Clin. Endocrinol. Metab. 58: 786, 1984.

    Article  PubMed  CAS  Google Scholar 

  18. Azzarito C., Boiardi L., Vergoni W., Zini M., Portioli I. Testicular function in hypercholesterolemic male patients during prolonged simvastatin treatment. Horm. Metab. Res. 28: 193, 1996.

    Article  PubMed  CAS  Google Scholar 

  19. Rossato M., Guarneri G., Lavagnini T., Padovan D., Foresta C. Simvastatin influences testicular steroidogenesis in human. Horm. Metab. Res. 25: 503, 1993.

    Article  PubMed  CAS  Google Scholar 

  20. Dobs A.S., Sarma P.S., Schteingart D. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Metabolism 42: 1146, 1993.

    Article  PubMed  CAS  Google Scholar 

  21. Travia D., Tosi F., Negri C., Faccini G., Moghetti P., Muggeo M. Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads. J. Clin. Endocrinol. Metab. 80: 836, 1995.

    PubMed  CAS  Google Scholar 

  22. MacDonald J.S., Gerson R.J., Kommst D.J., Kloss M.W., Prahalada S., Berry P.H., Alberts A.W., Bokelman D.L. Preclinical evaluation of lovastatin. Am. J. Cardiol. 62: 16J, 1988.

    Article  PubMed  CAS  Google Scholar 

  23. Purvis K., Tollefsrud A., Rui H., Hang E., Norseth J., Viksmoen L., Ose L., Lund H. Short-term effects of treatment with simvastatin on testicular function in patients with heterozygous familial hypercholesterolemia. Eur. J. Clin. Pharmacol. 42: 61, 1992.

    Article  PubMed  CAS  Google Scholar 

  24. Bernini G.P., Argenio G.F., Gasperi M., Vivaldi M.S., Franchi F., Salvetti A. Effects of long-term simvastatin treatment on testicular and adrenal steroidogenesis in hypercholesterolemic patients. J. Endocrinol. Invest 17: 227, 1994.

    Article  PubMed  CAS  Google Scholar 

  25. Germershansen J.I., Hunt U.M., Bostedor R.G., Bailey P.J., Karkas J.D., Alberts A.W. Tissue selectivity of the cholesterol lowering agent lovastatin, simvastatin and pravastatin in rats in vivo. Biochem. Biophys. Res. Commun. 158: 667, 1989.

    Article  Google Scholar 

  26. Koga T., Shimada Y., Kuroda M., Tsujita Y., Hasegawa K., Yamazaki M. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3 hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor. Biochem. Biophys. Acta 1045: 1115, 1990.

    Article  Google Scholar 

  27. Kuroda M., Hatsumoto A., Itakura H., Watanabe Y., Ito T., Shiomi M., Fukushige J., Nara F., Fukami M., Tsujita Y. Effects of pravastatin sodium alone and in combination with cholestiramina on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe hevitable hyperlipidemic rabbits. Jpn. J. Pharmacol. 59: 65, 1992.

    Article  PubMed  CAS  Google Scholar 

  28. Simpson E.R., Carr B.R., Parker C.R. Jr, Milewich L., Porter J.C., MacDonald P.C. The role of serum lipoproteins in steroidogenesis by the human fetal adrenal cortex. J Clin. Endocrinol. Metab. 49: 146, 1979.

    Article  PubMed  CAS  Google Scholar 

  29. Engelhard H., Gore-Langton R.E., Armstrong D.T. Mevinolin (lovastatin) inhibits androstenedione production by porcine ovarian theca cells at the level of 17 x hydroxylase: C17, 20-lyase complex. Endocrinology 124: 2297, 1989.

    Article  Google Scholar 

  30. Kovanen P.T., Bilheimer D.W., Goldstein J.L., Jaramillo J.J., Brown M.S. Regulatory rate for hepatic low density lipoproteins in vivo in the dog. Proc. Natl. Acad. Sci. USA 78: 1194, 1981.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  31. Gerson R.J., MacDonald J.S., Alberts A.W., Kornhrust D.J., Majka J.A., Stubbs R.J., Bokelman D.L. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-Coenzyme A Reductase inhibitors. Am. J. Med. 87(suppl. 4A): 28S, 1989.

    Article  PubMed  CAS  Google Scholar 

  32. Smals A.G.H., Weusten J.A.M., Benraad T.J., Kloppenborg P.W.C. The HMG-CoA reductase inhibitor simvastatin suppresses human testicular testosterone synthesis in vitro by a selective inhibitory effect on 17-ketosteroid-oxydoreductase enzyme activity. J. Steroid Biochem. Mol. Biol. 38: 465, 1991.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Interna, Istituto di Clinica Medica I, University of Pisa, Via Roma 67, 56100, Pisa, Italy

    G. P. Bernini, G. Brogi, G. F. Argenio, A. Moretti & A. Salvetti

Authors
  1. G. P. Bernini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Brogi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. F. Argenio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Moretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Salvetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bernini, G.P., Brogi, G., Argenio, G.F. et al. Effects of long-term pravastatin treatment on spermatogenesis and on adrenal and testicular steroidogenesis in male hypercholesterolemic patients. J Endocrinol Invest 21, 310–317 (1998). https://doi.org/10.1007/BF03350334

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03350334

Key-words

Search

Navigation